ReviewCirculation2022

GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes.

Nikolaus Marx et al.PubMed ↗Publisher ↗

No numbers read from the abstract.